Phase 1 approval for lead chronic pain drug

London, UK –News Direct– Oxford Cannabinoid Technologies Holdings PLC

Proactive research analyst Daniel Appiah speaks to Thomas Warner after publishing a research note on Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF), entitled “Phase 1 approval for lead chronic pain drug.” Oxford Cannabinoid Technologies Holdings CEO Clarissa Sowemimo-Coker recently told Proactive’s Stephen Gunnion that Medicines and Healthcare products Regulatory Agency (MHRA) approval of a phase 1 trial for its lead pain relief drug candidate, OCT461201, represents a significant milestone for the company.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

View original content to download multimedia:

This news release was distributed by News Direct Corp. (“News Direct”). News Direct is an industry-leading content and news distribution platform. This news release and all materials included within this news release, including, without limitation, all images, trademarks and logos, are protected by copyrights, trademarks, service marks, patents or other proprietary rights and laws. If you copy, broadcast, download, store (in any medium), transmit, show or play any multimedia content from this release in public, you must properly attribute said content to the company or organization from which the news release originated unless otherwise sourced. News Direct makes no warranties with respect to the accuracy or completeness of the information contained in this news release. News Direct hereby disclaims all warranties, whether express, implied, statutory or otherwise, in connection with this news release and the content within this news release.

Read more here: Source link

Leave a Reply

Your email address will not be published. Required fields are marked *